Robert Abouassaly, MD

Articles by Robert Abouassaly, MD

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

BySimon P. Kim, MD, MPH,Cary P. Gross, MD,Quoc-Dien Trinh, MD,Marc C. Smaldone, MD, MSHP,R. Houston Thompson, MD,Sarah P. Psutka, MD,Holly Van Houten, BA,Leona C. Han, BA,Robert Abouassaly, MD

February 12th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Latest Updated Articles

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma
Published: February 12th 2016 | Updated:

Robert Abouassaly, MD

Articles by Robert Abouassaly, MD

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Latest Updated Articles

Trending on Pharmacy Times

GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders

Young Women With Symptomatic Long COVID At Higher Risk of POTS

OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why

FDA Approves Updated Indication for Upadacitinib in Patients With IBD

Breaking News: CVS Buys Rite Aid, Bartell Drugs